Stocks & Investing
Stocks and Investing
Stocks and Investing
Fri, July 9, 2021
[ Fri, Jul 09th 2021
] - WOPRAI
[ Fri, Jul 09th 2021
] - WOPRAI
[ Fri, Jul 09th 2021
] - WOPRAI
Thu, July 8, 2021
[ Thu, Jul 08th 2021
] - WOPRAI
[ Thu, Jul 08th 2021
] - WOPRAI
[ Thu, Jul 08th 2021
] - WOPRAI
[ Thu, Jul 08th 2021
] - WOPRAI
[ Thu, Jul 08th 2021
] - WOPRAI
[ Thu, Jul 08th 2021
] - WOPRAI
[ Thu, Jul 08th 2021
] - WOPRAI
[ Thu, Jul 08th 2021
] - WOPRAI
[ Thu, Jul 08th 2021
] - WOPRAI
[ Thu, Jul 08th 2021
] - WOPRAI
[ Thu, Jul 08th 2021
] - WOPRAI
[ Thu, Jul 08th 2021
] - WOPRAI
[ Thu, Jul 08th 2021
] - WOPRAI
[ Thu, Jul 08th 2021
] - WOPRAI
[ Thu, Jul 08th 2021
] - WOPRAI
[ Thu, Jul 08th 2021
] - WOPRAI
[ Thu, Jul 08th 2021
] - WOPRAI
[ Thu, Jul 08th 2021
] - WOPRAI
[ Thu, Jul 08th 2021
] - WOPRAI
[ Thu, Jul 08th 2021
] - WOPRAI
[ Thu, Jul 08th 2021
] - WOPRAI
[ Thu, Jul 08th 2021
] - WOPRAI
Matthew Luchini Maintained (APLS) at Buy with Increased Target to $89 on, Jul 8th, 2021
Matthew Luchini of BMO Capital, Maintained "Apellis Pharmaceuticals, Inc." (APLS) at Buy with Increased Target from $68 to $89 on, Jul 8th, 2021.
Matthew has made no other calls on APLS in the last 4 months.
There are 5 other peers that have a rating on APLS. Out of the 5 peers that are also analyzing APLS, 1 agrees with Matthew's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Tiago Fauth of "Credit Suisse" Maintained at Hold with Increased Target to $39 on, Thursday, April 29th, 2021
These are the ratings of the 4 analyists that currently disagree with Matthew
- Anupam Rama of "JP Morgan" Maintained at Buy with Increased Target to $101 on, Friday, July 2nd, 2021
- Joseph Stringer of "Needham" Maintained at Strong Buy with Increased Target to $85 on, Monday, June 28th, 2021
- Eliana Merle of "UBS" Initiated at Strong Buy and Held Target at $82 on, Friday, May 21st, 2021
- Madhu Kumar of "Goldman Sachs" Initiated at Strong Buy and Held Target at $130 on, Friday, April 16th, 2021
